|
시장보고서
상품코드
2032823
호중구 감소증 치료 시장 보고서 : 치료법별, 유통 채널별, 지역별(2026-2034년)Neutropenia Treatment Market Report by Treatment (Colony-Stimulating Factors, Antibiotics, Antifungals, Antivirals), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2026-2034 |
||||||
세계의 호중구 감소증 치료 시장 규모는 2025년에 168억 달러에 이르렀습니다. IMARC Group은 향후 2034년까지 시장 규모가 254억 달러에 이를 전망이며, 2026-2034년 CAGR 4.54%로 성장할 것으로 예측했습니다. 클라우드 플랫폼의 보급 확대, 스마트폰 판매 증가, 활발한 연구개발(R&D) 활동 등이 시장을 견인하는 주요 요인으로 작용하고 있습니다.
호중구 감소증은 신체가 감염과 싸우는 데 도움을 주는 백혈구(WBC)의 수가 비정상적으로 적은 것이 특징인 질환입니다. 감염, 화학요법, 선천성 골수 이상, 자가면역질환, 일부 약물(약제성 호중구 감소증) 등 다양한 상황과 질환에 의해 발생합니다. 호중구는 골수에서 생성됩니다. 골수는 척추, 갈비뼈, 골반 등 큰 뼈에서 발견되는 해면체 조직을 말합니다. 호중구 감소증 치료에는 항생제, 항진균제, 항바이러스제 등이 사용됩니다. 이들은 인체를 공격하는 유해한 곰팡이, 효모, 박테리아를 파괴하여 감염과 싸우는 데 도움을 줍니다. 이 약제들은 감염증의 발병 위험을 감소시키고 골수를 자극하여 더 많은 백혈구를 생성하도록 하는 작용을 합니다.
호중구 감소증 치료 시장 동향 :
호중구 감소증 및 화학요법 관련 부작용에 대한 인식이 높아지면서 시장 성장을 이끄는 주요 요인 중 하나입니다. 이에 따라 캡슐이나 정제 형태로 제공되어 복용이 용이한 경구용 의약품에 대한 수요가 증가하면서 시장 성장을 견인하고 있습니다. 또한, 주요 기업들은 호중구 감소증 예방책, 조기 진단 및 효과적인 치료에 대한 관련 정보 및 지식의 보급에 적극적으로 노력하고 있으며, 이는 시장 성장을 가속하고 있습니다. 또한, 이용 가능한 치료 옵션에 대한 대중의 인식이 높아진 것도 시장 성장을 가속하는 또 다른 요인으로 작용하고 있습니다. 또한, 각 제조업체들은 호중구 감소증 치료를 위한 비용 효율적인 의약품 도입에 주력하고 있으며, 이는 시장 성장을 견인하고 있습니다. 또한, 환자의 편의성을 향상시키고 복약 순응도를 높일 수 있는 새로운 약물 전달 방법의 활용도 시장 성장에 긍정적인 영향을 미치고 있습니다. 여기에 발열성 호중구 감소증 치료 증가와 바이오시밀러의 촉진 및 제조를 목적으로 하는 새로운 법의 시행으로 시장 전망이 밝아지고 있습니다. 또한, 등록된 웹사이트 등 온라인 소매 포털을 통해 의약품을 쉽게 구할 수 있는 것도 시장 성장 요인으로 작용하고 있으며, 저렴한 가격으로 의약품을 주문 및 구매할 수 있는 편리함을 제공합니다. 또한, 광범위한 연구개발(R&D) 활동, 혁신적이고 효과적인 의약품의 도입, 암 발병률 증가, 인프라 개선으로 인한 의료 시설 접근성 향상, 소비자의 구매력 향상, 공중보건 증진을 위한 다양한 정부 정책 시행 등이 시장 성장을 견인할 것으로 예측됩니다.
목차
제1장 서문
제2장 조사 범위 및 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 호중구 감소증 치료 시장
제6장 시장 내역 : 치료별
제7장 시장 내역 : 유통 채널별
제8장 시장 내역 : 지역별
제9장 촉진요인, 억제요인 및 기회
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
AJY 26.05.19The global neutropenia treatment market size reached USD 16.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.54% during 2026-2034. The increasing adoption of cloud platforms, escalating sales of smartphones and extensive research and development (R&D) activities represent some of the key factors driving the market.
Neutropenia is a disease characterized by an abnormally low count of white blood cells (WBCs) that help the body fight infections. It is caused by various situations or diseases, including infections, chemotherapy, congenital bone marrow abnormalities, autoimmune disorders, and some medications (drug-induced neutropenia). Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones, such as the vertebrae, ribs, and pelvis. Neutropenia treatment includes antibiotics, antifungals, and antiviral medications that help fight against infection by destroying harmful fungi, yeast , and bacteria that attack the body. These medications assist in reducing the likelihood of infections and stimulate the bone marrow to produce more white blood cells.
NEUTROPENIA TREATMENT MARKET TRENDS:
The rising awareness of neutropenia and chemotherapy-related side effects is one of the key factors driving the market growth. In line with this, the increasing demand for oral drugs that are available in capsule and tablet form and consist of convenient routes of administration is favoring the market growth. Moreover, key players are actively engaged in disseminating relevant information and knowledge regarding preventive measures, early diagnosis, and effective treatment of neutropenia, which, in turn, is propelling the market growth. Furthermore, the increasing awareness among the masses regarding the available treatment alternatives is acting as another growth-inducing factor. In addition to this, manufacturers are focusing on the introduction of cost-effective medicines for neutropenia treatment, which is facilitating the market growth. Additionally, the utilization of novel drug delivery methods that helps in improving patient convenience, which leads to improved patient adherence, is positively influencing the market growth. Besides this, the increase in febrile neutropenia medications and the implementation of new legislation to promote and manufacture biosimilars are creating a positive outlook for the market. The market is also driven by the easy availability of medications through online retail portals, such as registered websites, which provides convenience of ordering and procurement of medications at affordable price-points. Other factors, including extensive research and development (R&D) activities, the introduction of innovative and effective drugs, rising incidences of cancer, easy access to healthcare facilities owing to improved infrastructure, increasing expenditure capacities of consumers and the implementation of various government initiatives for promoting public health, are anticipated to drive the market growth.
KEY MARKET SEGMENTATION:
Treatment Insights:
- Colony-Stimulating Factors
- Antibiotics
- Antifungals
- Antivirals
Distribution channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for neutropenia treatment. Some of the factors driving the North America neutropenia treatment market included increasing demand for internet-enabled services by enterprises, extensive research and development (R&D) activities, and various technological advancements.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global neutropenia treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited), Pfizer Inc., Sandoz Inc. (Novartis AG), Spectrum Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Neutropenia Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment
- 6.1 Colony-Stimulating Factors
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Antibiotics
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Antifungals
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Antivirals
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Distribution Channel
- 7.1 Hospital Pharmacies
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Retail Pharmacies
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Online Pharmacies
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 Drivers, Restraints, and Opportunities
- 9.1 Overview
- 9.2 Drivers
- 9.3 Restraints
- 9.4 Opportunities
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Amgen Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 BeyondSpring Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.3 Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited)
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Pfizer Inc.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Sandoz Inc. (Novartis AG)
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 SWOT Analysis
- 13.3.6 Spectrum Pharmaceuticals Inc.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Teva Pharmaceutical Industries Ltd.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Viatris Inc.
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.1 Amgen Inc.
